SHP-1 suppresses endotoxin-induced uveitis by inhibiting the TAK1/JNK pathway

J Cell Mol Med. 2021 Jan;25(1):147-160. doi: 10.1111/jcmm.15888. Epub 2020 Nov 18.

Abstract

We investigated how Src-homology 2-domain phosphatase-1 (SHP-1) regulates the inflammatory response in endotoxin-induced uveitis (EIU), and the signalling pathways involved. One week after intravitreal injection of short hairpin RNA targeting SHP-1 or SHP-1 overexpression lentivirus in rats, we induced ocular inflammation with an intravitreal injection of lipopolysaccharide (LPS). We then assessed the extent of inflammation and performed full-field electroretinography. The concentrations and retinal expression of various inflammatory mediators were examined with enzyme-linked immunosorbent assays and Western blotting, respectively. SHP-1 overexpression and knockdown were induced in Müller cells to study the role of SHP-1 in the LPS-induced inflammatory response in vitro. Retinal SHP-1 expression was up-regulated by LPS. SHP-1 knockdown exacerbated LPS-induced retinal dysfunction and increased the levels of proinflammatory mediators in the retina, which was abrogated by a c-Jun N-terminal kinase (JNK) inhibitor (SP600125). SHP-1 overexpression had the opposite effects. In Müller cells, the LPS-induced inflammatory response was enhanced by SHP-1 knockdown and suppressed by SHP-1 overexpression. SHP-1 negatively regulated the activation of the transforming growth factor-β-activated kinase-1 (TAK1)/JNK pathway, but not the nuclear factor-κB pathway. These results indicate that SHP-1 represses EIU, at least in part, by inhibiting the TAK1/JNK pathway and suggest that SHP-1 is a potential therapeutic target for uveitis.

Keywords: JNK; LPS; Müller cells; SHP-1; inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anterior Chamber / drug effects
  • Anterior Chamber / pathology
  • Aqueous Humor / metabolism
  • Cytokines / metabolism
  • Down-Regulation / drug effects
  • Endotoxins
  • Ependymoglial Cells / drug effects
  • Ependymoglial Cells / metabolism
  • Inflammation / pathology
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Lipopolysaccharides / pharmacology
  • MAP Kinase Kinase Kinases / metabolism*
  • Male
  • Protein Tyrosine Phosphatase, Non-Receptor Type 6 / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Retina / drug effects
  • Retina / metabolism
  • Retina / pathology
  • Retina / physiopathology
  • Up-Regulation / drug effects
  • Uveitis / chemically induced*
  • Uveitis / metabolism*
  • Uveitis / pathology
  • Vitreous Body / drug effects
  • Vitreous Body / pathology

Substances

  • Cytokines
  • Endotoxins
  • Lipopolysaccharides
  • JNK Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinases
  • MAP kinase kinase kinase 7
  • Protein Tyrosine Phosphatase, Non-Receptor Type 6
  • Ptpn6 protein, rat